Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

被引:10
|
作者
Crepey, Pascal [1 ]
Boiron, Louis [2 ]
Araujo, Rafael Rodrigo [2 ]
Lopez, Juan Guillermo [3 ]
Petitjean, Audrey [4 ]
de Albuquerque Luna, Expedito Jose [5 ]
机构
[1] Univ Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
[2] Sanofi Pasteur, Av Nacoes Unidas,14410 Condominio Parque, BR-04794000 Sao Paulo, SP, Brazil
[3] Sanofi Pasteur, Av Univ 1738, Ciudad De Mexico 04000, Cdmx, Mexico
[4] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
[5] Univ Sao Paulo, Inst Trop Med IMT, Av Dr Eneas Carvalho Aguiar,470 Jardim Amer, BR-05403000 Sao Paulo, SP, Brazil
关键词
QIV; Quadrivalent; Public health; Cost-effectiveness; Vaccine; Influenza; Brazil; PUBLIC-HEALTH IMPACT; SEASONAL INFLUENZA; BURDEN;
D O I
10.1186/s12889-020-09409-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. Methods We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. Results Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. Conclusions Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom
    Edward W. Thommes
    Afisi Ismaila
    Ayman Chit
    Genevieve Meier
    Christopher T. Bauch
    [J]. BMC Infectious Diseases, 15
  • [22] Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom
    Thommes, Edward W.
    Ismaila, Afisi
    Chit, Ayman
    Meier, Genevieve
    Bauch, Christopher T.
    [J]. BMC INFECTIOUS DISEASES, 2015, 15
  • [23] Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
    You, Joyce H. S.
    Ming, Wai-kit
    Chan, Paul K. S.
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [24] Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
    Joyce HS You
    Wai-kit Ming
    Paul KS Chan
    [J]. BMC Infectious Diseases, 14
  • [25] A COST EFFECTIVENESS ANALYSIS OF SEASONAL QUADRIVALENT INFLUENZA VACCINE IN ITALY USING A STATIC MODEL
    Mennini, F. S.
    Bini, C.
    Marcellusi, A.
    Rinaldi, A.
    Franco, E.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A788 - A789
  • [26] Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
    Yun-Kyung Kim
    Joon Young Song
    Hyeongap Jang
    Tae Hyun Kim
    Heejo Koo
    Lijoy Varghese
    Euna Han
    [J]. PharmacoEconomics, 2018, 36 : 1475 - 1490
  • [27] Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
    Kim, Yun-Kyung
    Song, Joon Young
    Jang, Hyeongap
    Kim, Tae Hyun
    Koo, Heejo
    Varghese, Lijoy
    Han, Euna
    [J]. PHARMACOECONOMICS, 2018, 36 (12) : 1475 - 1490
  • [28] COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL
    Almeida, J.
    Ferreira, C.
    Monteiro, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S651 - S651
  • [29] The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
    Kohli, Michele A.
    Maschio, Michael
    Mould-Quevedo, Joaquin F.
    Drummond, Michael
    Weinstein, Milton C.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (11) : 4603 - 4610
  • [30] Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population
    Rumi, Filippo
    Basile, Michele
    Cicchetti, Americo
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 105 - 113